CASO CLINICO Il paziente naϊve ad alta viremia.

Slides:



Advertisements
Similar presentations
Case Discussion: HIV resistance and salvage regimens The 3 rd HIV-NAT Symposium Series Wasana Prasitsuebsai, MD, MPH 25 th July 2013.
Advertisements

Line Efficiency     Percentage Month Today’s Date
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.
CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Prevention and Care Dr S Charalambous WHO guidelines.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
Profili di resistenza e barriera genetica dei nuovi trattamenti antiretrovirali Carlo Federico Perno Catania 10 Novembre 2015.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
Switch to PI/r monotherapy
Windows Server 2008 R2 Oct 2009 Windows Server 2003
Comparison of PI vs PI ATV vs ATV/r BMS 089
Jan 2016 Solar Lunar Data.
Phylogenetic relationships of HIV-1 Pol RT strains
IT Strategy Roadmap Template
Introduction Results Objectives Methods Conclusion Funding
Q1 Jan Feb Mar ENTER TEXT HERE Notes
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun

Project timeline # 3 Step # 3 is about x, y and z # 2
Average Monthly Temperature and Rainfall
ABT & Frequency.

2017 Jan Sun Mon Tue Wed Thu Fri Sat

FOMEMA Sales Review Clinic Management Meeting
Gantt Chart Enter Year Here Activities Jan Feb Mar Apr May Jun Jul Aug
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Free PPT Diagrams : ALLPPT.com

Results of round 1 of the Delphi survey
Step 3 Step 2 Step 1 Put your text here Put your text here
Calendar Year 2009 Insure Oklahoma Total & Projected Enrollment
Jan Sun Mon Tue Wed Thu Fri Sat
©G Dear 2008 – Not to be sold/Free to use
Electricity Cost and Use – FY 2016 and FY 2017
ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.
Switch to DRV/r monotherapy

Comparison of PI vs PI ATV vs ATV/r BMS 089
©G Dear 2010 – Not to be sold/Free to use
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Comparison of PI vs PI ATV vs ATV/r BMS 089
Free PPT Diagrams : ALLPPT.com
CASO CLINICO Il paziente naϊve con resistenze al basale.

Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Project timeline # 3 Step # 3 is about x, y and z # 2
TIMELINE NAME OF PROJECT Today 2016 Jan Feb Mar Apr May Jun

Resistance in the age of Integrases
Comparison of NNRTI vs NNRTI
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Comparison of PI vs PI ATV vs ATV/r BMS 089
Presentation transcript:

CASO CLINICO Il paziente naϊve ad alta viremia

Viremia: >500000 copies/ml CD4: 243 cells/µl Risk Factor MSM Clinical Case: ID 7200 Patient with HIV-1 CRF12_BF subtype Age 45 Sex M CDC stage B2 I Seropositivity January 2008 in out Feb-08 Apr-08 May-08 Jul-08 Oct-08 Jan-09 Apr-09 Jul-09 Jan-10 Apr-10 Aug-10 Nov-10 Mar-11 Jun-11 Nov-11 Mar-12 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Viremia (log copies/ml) 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 CD4 cell count (cells/ul) >500000 cps/ml Undetectability threshold 6.5 GRT February 2008 PR: L10V RT: None Other pol mutations PR: K14KR, I15V, G17D, E35D, M36I, R41K, R57K, Q61N I93L RT: V35T, V60I, K122E, D123A, I135IT, I142IT, I178IM, I195IL, G196E, A272P, T286A, I293V, E297K On February 2008 Viremia: >500000 copies/ml CD4: 243 cells/µl Rapid achievement of virological response and maintenance of undetectability in patient with very high pre-HAART viremia FEB ‘08 – MAR ‘12 TDF+FTC, EFV

Clinical Case: ID 7200 Patient I Seropositivity January 2008 Risk Factor MSM Clinical Case: ID 7200 Patient with HIV-1 CRF12_BF subtype Age 45 Sex M CDC stage B2 I Seropositivity January 2008 Mutation scoring* for the protease PR  ATV/r  DRV/r  FPV/r  IDV/r  LPV/r  NFV  SQV/r  TPV/r  L10V 5 Total:  GRT March 2008 Mutation scoring* for the reverse transcriptase RT  3TC  ABC  AZT  D4T  DDI  FTC  TDF  EFV ETR NVP RPV Total:  GRT March 2008 * Stanford Algorithm (http:hivdb.stanford.edu) Susceptible virus